BioSpace News Archive

Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) announced that, based on a preliminary vote count, its stockholders have adopted the previously announced merger agreement providing for the merger with MEI Pharma, Inc. (“MEI”) at the special meeting of Infinity stockholders held earlier today (the “Special Meeting”).

Cadrenal Therapeutics, Inc. announced that it has closed its previously announced private placement with an institutional investor for the issuance and sale of 4,285,715 of its shares of common stock at a purchase price of $1.75 per share priced at-the-market under Nasdaq rules.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio) today announced that members of its management team will host an investor call on Monday, July 17 at 8:00 am ET to share topline results from the Phase 3 ATTRibute-CM clinical study in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).